New hope for lung scarring: HSK44459 enters final trial phase
NCT ID NCT07519070
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new tablet, HSK44459, for people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. About 420 adults aged 40 and older will receive either the drug or a placebo for 52 weeks. The main goal is to see if the drug helps maintain lung function and reduces flare-ups or hospital stays.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a breath test predict lung scarring? new study seeks answers
- New inhaled drug for lung disease tested in healthy people first
- Healthy volunteers to test experimental lung disease drug
- New drug for lung scarring takes first step in healthy volunteers
- Simple questionnaire could bring palliative care home for lung disease patients
- New drug MN-001 tested for scarred lungs in tiny trial